| Schedule of Segment Reporting Financial Information |
The following table presents selected financial information with respect to the Company’s single operating segment for the years ended September 30, 2026, 2025, and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2024 |
|
Revenue |
|
|
|
|
|
|
|
|
|
Royalty revenue |
|
$ |
63,001 |
|
|
$ |
65,324 |
|
|
$ |
67,635 |
|
Total revenue |
|
|
63,001 |
|
|
|
65,324 |
|
|
|
67,635 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
RSV |
|
|
25,898 |
|
|
|
59,808 |
|
|
|
86,367 |
|
Total virology |
|
|
25,898 |
|
|
|
59,808 |
|
|
|
86,367 |
|
KIT |
|
|
17,067 |
|
|
|
18,052 |
|
|
|
19,822 |
|
STAT6 |
|
|
25,543 |
|
|
|
16,614 |
|
|
|
4,691 |
|
MRGPRX2 |
|
|
12,393 |
|
|
|
9,114 |
|
|
|
6,525 |
|
Total immunology |
|
|
55,003 |
|
|
|
43,780 |
|
|
|
31,038 |
|
Early discovery |
|
|
6,869 |
|
|
|
2,214 |
|
|
|
8,471 |
|
Other pipeline programs |
|
|
776 |
|
|
|
938 |
|
|
|
5,600 |
|
Total other programs |
|
|
7,645 |
|
|
|
3,152 |
|
|
|
14,071 |
|
General and administrative |
|
|
36,835 |
|
|
|
43,933 |
|
|
|
57,850 |
|
Total operating expenses |
|
|
125,381 |
|
|
|
150,673 |
|
|
|
189,326 |
|
Loss from operations |
|
|
(62,380 |
) |
|
|
(85,349 |
) |
|
|
(121,691 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(14,074 |
) |
|
|
(7,681 |
) |
|
|
(10,940 |
) |
Interest and investment income, net |
|
|
8,225 |
|
|
|
9,442 |
|
|
|
14,770 |
|
Change in fair value of Series 1 nonconvertible preferred stock |
|
|
21 |
|
|
|
39 |
|
|
|
73 |
|
Total other income (expense), net |
|
|
(5,828 |
) |
|
|
1,800 |
|
|
|
3,903 |
|
Loss before income taxes |
|
|
(68,208 |
) |
|
|
(83,549 |
) |
|
|
(117,788 |
) |
Income tax benefit (expense) |
|
|
(40 |
) |
|
|
1,660 |
|
|
|
1,743 |
|
Net loss |
|
$ |
(68,248 |
) |
|
$ |
(81,889 |
) |
|
$ |
(116,045 |
) |
|